



truScreen  
a world without  
cervical cancer

## NZX/ASX Announcement

19 December 2022

### Distributor Update

Cervical cancer screening technology company, **TruScreen Group Limited** (NZX/ASX: TRU) ('TruScreen' or 'the Company'), is pleased to provide this update on Distributor progress in November/December 2022.

#### *Poland*

TruScreen has recently been recognised and awarded the Quality and Innovation Mark by the Polish Medical University of Lodz. Lodz is the fourth largest city in Poland. The Polish University of Technology, Lodz has also delivered a positive technical opinion on the TruScreen cervical cancer screening device, led by Dr Anna Lipert. TruScreen is currently in discussion with a private network of medical clinics, with 26 gynaecologists, to roll out the TruScreen cervical cancer screening device to these centres.



II Fall Congress Academy of Gynaecology and Obstetrics, Poland 11-14 October 2022



Quality and Innovation Mark – Polish University of Lodz

#### *Zimbabwe*

The TruScreen cervical cancer screening roll out by National Aids Council (NAC) in Zimbabwe continues to make excellent progress. There has been a significant uptake following the ongoing outreach programme by the NAC. The target of this phase is to reach 10,000 women in the Masvingo province by the end of January 2023. The sixteen TruScreen devices in operation throughout the region screened an average of 171 women per device in November with 376 per device being the highest recorded to date.

TruScreen has recently submitted a tender for the supply of a further 10,800 SUS (Single Use Sensor) which it is expected will be supplied in early 2023.

### *Vietnam*

A TruScreen seminar hosted by Tu Du Hospital, the most influential gynaecological hospital in South Vietnam, was held on 13 December and received substantial interest and positive feedback on the performance of TruScreen. The seminar was attended by more than 100 doctors.

Dr Jerry Tan, General Manager Commercial, has recently completed a 7 day visit to Vietnam, attending the Tu Du seminar, and participating in a charity project in the Central Highlands funded by the distributor Gorton Health Services (GHS), which screened 1,000 local women. This initiative received strong support and acclaim from the local government and opened the door for TruScreen to enter a region with a population of nearly 6 million. During the visit, Dr. Tan met with Key Opinion Leaders and officials from the various hospitals to provide further training and assistance to our local distributor.

Vietnam has placed an order for 8 devices and 1,800 SUS which will be supplied in early 2023, to be installed in 8 hospitals with screenings expected to commence in Q1 2023.

### *Russia/Kazakhstan*

TruScreen's Russia distributor JSC IMSystems has extended its presence to Kazakhstan. Kazakhstan has a population of 18 million spread over an area of 2.7 million square kilometres (the 9<sup>th</sup> largest country in the world).

TruScreen has recently received an order for 5 TruScreen devices and 6,120 SUS which will accelerate cervical cancer screening programmes in Russia and surrounding Central Asian countries. Most doctors and clinicians in Kazakhstan, Kyrgyzstan, Armenia, and other Central Asian nations are trained in Russia.

This announcement has been approved by the Board.

For more information, visit [www.truscreen.com](http://www.truscreen.com) or contact:

Dr Beata Edling  
Chief Executive Officer  
[beataedling@truscreen.com](mailto:beataedling@truscreen.com)

Guy Robertson  
Chief Financial Officer  
[guyrobertson@truscreen.com](mailto:guyrobertson@truscreen.com)

Julia Maguire  
Investor Relations  
[julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)

## About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that has developed and manufactures an AI-enabled device for detecting abnormalities in the cervical tissue in real-time via measurements of the low level of optical and electrical stimuli.

TruScreen's technology enables cervical screening, without the need for sampling and processing of biological tissues, avoiding failed samples, missed follow-up and discomfort, and negating the need for costly, specialised personnel and supporting laboratory infrastructure.

The TruScreen device, TruScreen® Ultra, is registered as a primary screening tool for cervical cancer screening.

The device is EC certified, ISO 13485 compliant and is registered for clinical use with the TGA (Australia), MHRA (UK), NMPA (China), SFDA (Saudi Arabia), Roszdravnadzor (Russia), and COFEPRIS (Mexico). It has Ministry of Health approval for use in Vietnam, Zimbabwe, Israel, Ukraine, and the Philippines, among others and has active distribution agreements in 23 countries. It is also National Medical Products Administration approved for sale in China. In 2021, TruScreen established a manufacturing facility in China for devices marketed and sold in China.

To date, over 170,000\* examinations have been performed with the TruScreen device and over 200 devices have been installed and used in China, Vietnam, Mexico, Zimbabwe, Russia, and Saudi Arabia. TruScreen's vision is "A world without the cervical cancer".

To learn more, please visit: [www.truscreen.com/](http://www.truscreen.com/).

*\*Based on Single Disposable Sheath sales.*